A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age55+
SponsorEli Lilly and Company
About this trial
The purpose of this study is to test the use of a screening tool to detect changes in the eye that are associated with Alzheimer's disease in adult participants with memory issues. For each participant, the study will last up to one month and requires one visit to the research site.
Eligibility criteria
Qualifiers
Participants who are overtly healthy as determined by medical evaluation, including medical history and physical examination.
Have mild memory complaints or a diagnosis of mild cognitive impairment.
Have undergone genotyping for apolipoprotein E (APOE) and are willing to make results available to the investigator.
Montreal Cognitive Assessment (MoCA) score of greater than or equal to 22 and less than or equal to 28.
Disqualifiers
Have any medical condition that, in the opinion of the investigator, would be a contraindication to participation in the study.
Have an existing diagnosis of AD or other dementia.
Have contradictions to or an allergy to the ophthalmic dilating agents.
Have known diagnosis of severe glaucoma or severe cataracts; have a significant refractive error (more than 12 diopters [D] of spherical equivalent refraction); or have any ocular media opacity that prevents imaging of the retina (that is, severe cataract). Note: mild to moderate cataracts or vision correction with glasses or contact lenses are not exclusion criteria.
Trial design
Treatments tested in this trial
- Retinal scan
- Blood test
Treatment groups
200 Participants
are divided into 1 treatment groupLocations
1Cleveland Clinic Abu Dhabi Abu Dhabi United Arab Emirates
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov